Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To date, there is no prospective study that specifically investigated the efficacy of infliximab in intestinal Behçet’s disease (BD). This study evaluated the efficacy of infliximab in patients with moderate-to-severe active intestinal BD that are refractory to conventional therapies. Methods: This phase 3, interventional, open-label, single-arm study evaluated clinical outcomes of infliximab treatment in patients with moderate-to-severe intestinal BD. The coprimary endpoints were clinical response, decrease in disease activity index for intestinal BD (DAIBD) score ≥20 from weeks 0 to 8 for the induction therapy and week 32 for the maintenance therapy. Results: A total of 33 patients entered the induction therapy and were treated with infliximab 5 mg/kg intravenously at weeks 0, 2, and 6. The mean DAIBD score changed from 90.8±40.1 at week 0 to 40.3±36.4 at week 8, with a significant mean change of 50.5±36.4 (95% confidence interval, 37.5 to 63.4; p<0.001). Thirty-one (93.9%) continued to receive 5 mg/kg infliximab every 8 weeks during the maintenance therapy. The mean change in the DAIBD score after the maintenance therapy was statistically significant (61.5±38.5; 95% confidence interval, 46.0 to 77.1; p<0.001, from weeks 0 to 32). The proportion of patients who maintained a clinical response was 92.3% at week 32. No severe adverse reactions occurred during the induction and maintenance therapies. Conclusions: This study provided evidence that infliximab 5 mg/kg induction and maintenance therapies are efficacious and well-tolerated in patients with moderate-to-severe active intestinal BD. (ClinicalTrials.gov identifier: NCT02505568)
Abstract
Background/Aims: To date, there is no prospective study that specifically investigated the efficacy of infliximab in intestinal Behçet’s disease (BD). This study evaluated the efficacy of infliximab in patients with moderate-to-severe active intestinal BD that are refractory to conventional therapies. Methods: This phase 3, interventional, open-label, single-arm study evaluated clinical outcomes of infliximab treatment in patients with moderate-to-severe intestinal BD. The coprimary endpoints were clinical response, decrease in disease activity index for intestinal BD (DAIBD) score ≥20 from weeks 0 to 8 for the induction therapy and week 32 for the maintenance therapy. Results: A total of 33 patients entered the induction therapy and were treated with infliximab 5 mg/kg intravenously at weeks 0, 2, and 6. The mean DAIBD score changed from 90.8±40.1 at week 0 to 40.3±36.4 at week 8, with a significant mean change of 50.5±36.4 (95% confidence interval, 37.5 to 63.4; p<0.001). Thirty-one (93.9%) continued to receive 5 mg/kg infliximab every 8 weeks during the maintenance therapy. The mean change in the DAIBD score after the maintenance therapy was statistically significant (61.5±38.5; 95% confidence interval, 46.0 to 77.1; p<0.001, from weeks 0 to 32). The proportion of patients who maintained a clinical response was 92.3% at week 32. No severe adverse reactions occurred during the induction and maintenance therapies. Conclusions: This study provided evidence that infliximab 5 mg/kg induction and maintenance therapies are efficacious and well-tolerated in patients with moderate-to-severe active intestinal BD. (ClinicalTrials.gov identifier: NCT02505568)
참고문헌 (26)
- Cheon JH, "An update on the diagnosis, treatment, and prognosis of intestinal Behçet’s disease", Curr Opin Rheumatol, 27, pp.24~31 (2015)
- Yong Eun Park, "Updated treatment strategies for intestinal Behçet’s disease", The Korean Journal of Internal Medicine, 33(1), pp.1~19 (2018), 대한내과학회[DOI]
- Gül A, "Behçet’s disease : an update on the pathogenesis", Clin Exp Rheumatol, 19(5 Suppl 24), pp.S6~S12 (2001)
- Kaneko S, "Characterization of T cells specific for an epitope of human 60-kD heat shock protein(HSP)in patients with Behcet's disease(BD)in Japan", Clin Exp Immunol, 108, pp.204~212 (1997)
- Yamashita N, "Role of gammadelta T lymphocytes in the development of Behçet’s disease", Clin Exp Immunol, 107, pp.241~247 (1997)
- 박지혜, "Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease", Gut and Liver, 12(6), pp.623~632 (2018), 거트앤리버 소화기연관학회협의회
- Tanida S, "Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease", Clin Gastroenterol Hepatol, 13, pp.940~948 (2015)
- Park Y, "Update on the treatment of Behcet’s disease of the small bowel with biologic agents", Curr Gastroenterol Rep, 22, pp.24~ (2020)
- Yasuo Suzuki, "Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study", Intestinal research, 19(3), pp.301~312 (2021), 대한장연구학회[DOI]
- Hibi T, "Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study", Medicine(Baltimore), 95, pp.e3863~ (2016)
- Cheon JH, "Development and validation of novel diagnostic criteria for intestinal Behçet’s disease in Korean patients with ileocolonic ulcers", Am J Gastroenterol, 104, pp.2492~2499 (2009)
- Cheon JH, "Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet’s disease", Inflamm Bowel Dis, 17, pp.605~613 (2011)
- Lee JH, "Efficacy of infliximab in intestinal Behçet’s disease : a Korean multicenter retrospective study", Inflamm Bowel Dis, 19, pp.1833~1838 (2013)
- Best WR, "Development of a Crohn’s Disease Activity Index : National Cooperative Crohn’s Disease Study", Gastroenterology, 70, pp.439~444 (1976)
- Shin SJ, "Chronological changes in the systemic manifestations of intestinal Behcet’s disease and their significance in diagnosis", Int J Colorectal Dis, 25, pp.1371~1376 (2010)
- Jung YS, "Long-term clinical outcomes of Crohn’s disease and intestinal Behcet’s disease", Inflamm Bowel Dis, 19, pp.99~105 (2013)
- Ma D, "Etanercept in the treatment of intestinal Behcet’s disease", Cell Biochem Biophys, 69, pp.735~739 (2014)
- Nagamu Inoue, "Long-term safety and efficacy of adalimumab for intestinal Behçet’s disease in the open label study following a phase 3 clinical trial", Intestinal research, 15(3), pp.395~401 (2017), 대한장연구학회
- Lopalco G, "Certolizumab pegol treatment in Behcet’s disease with different organ involvement : a multicenter retrospective observational study", Mod Rheumatol, 27, pp.1031~1035 (2017)
- Vitale A, "Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease", Clin Rheumatol, 36, pp.2063~2069 (2017)
- Juillerat P, "Therapies in inflammatory bowel disease patients with extraintestinal manifestations", Digestion, 101(Suppl 1), pp.83~97 (2020)
- Ronald Keller, "Quality of life in inflammatory bowel diseases: it is not all about the bowel", Intestinal research, 19(1), pp.45~52 (2021), 대한장연구학회[DOI]
- Greuter T, "Emerging treatment options for extraintestinal manifestations in IBD", Gut, 70, pp.796~802 (2021)
- Yim SM, "Mucosal healing predicts the long-term prognosis of intestinal Behçet’s disease", Dig Dis Sci, 59, pp.2529~2535 (2014)
- 박재준, "Outcome Predictors for Intestinal Behçet’s Disease", Yonsei Medical Journal, 54(5), pp.1084~1090 (2013), 연세대학교의과대학[DOI]
- Lichtenstein L, "Infliximab-related infusion reactions : systematic review", J Crohns Colitis, 9, pp.806~815 (2015)